Literature DB >> 21779511

p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer.

Susan M Mendrysa1, Sara Ghassemifar, Reem Malek.   

Abstract

The p53 tumor suppressor potently limits the growth of immature and mature neurons under conditions of cellular stress. Although loss of p53 function contributes to the pathogenesis of central nervous system (CNS) tumors, excessive p53 function is implicated in neural tube defects, embryonic lethality, and neuronal degeneration. Thus, p53 function must be tightly controlled. The anti-proliferative properties of p53 are mediated, in part, through the induction of apoptosis, cell cycle arrest, and senescence. Although there is still much to be learned about the role of p53 in these processes, recent evidence supports exciting new roles for p53 in a wide range of processes, including neural precursor cell self-renewal, differentiation, and cell fate decisions. Understanding the full repertoire of p53 function in CNS development and tumorigenesis may provide us with novel points of therapeutic intervention for human diseases of the CNS.

Entities:  

Keywords:  MDM2; MDM4; apoptosis; birth defects; cancer stem cell; glioblastoma; medulloblastoma; nervous system; neural stem cell; p53

Year:  2011        PMID: 21779511      PMCID: PMC3135640          DOI: 10.1177/1947601911409736

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  163 in total

1.  Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.

Authors:  E Gottlieb; R Haffner; A King; G Asher; P Gruss; P Lonai; M Oren
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

2.  p53 suppresses the self-renewal of adult neural stem cells.

Authors:  Konstantinos Meletis; Valtteri Wirta; Sanna-Maria Hede; Monica Nistér; Joakim Lundeberg; Jonas Frisén
Journal:  Development       Date:  2006-01       Impact factor: 6.868

3.  Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.

Authors:  Shu-Jie He; Graham Stevens; Antony W Braithwaite; Michael R Eccles
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

4.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53.

Authors:  W Tao; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  Altered neural cell fates and medulloblastoma in mouse patched mutants.

Authors:  L V Goodrich; L Milenković; K M Higgins; M P Scott
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

8.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

Review 9.  The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Authors:  Michael D Hogarty
Journal:  Cancer Lett       Date:  2003-07-18       Impact factor: 8.679

10.  p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing.

Authors:  M Badiali; A Iolascon; M Loda; B W Scheithauer; G Basso; G P Trentini; F Giangaspero
Journal:  Diagn Mol Pathol       Date:  1993-03
View more
  27 in total

1.  Introduction: The Changing Directions of p53 Research.

Authors:  Arnold J Levine
Journal:  Genes Cancer       Date:  2011-04

2.  p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.

Authors:  C Turnquist; I Horikawa; E Foran; E O Major; B Vojtesek; D P Lane; X Lu; B T Harris; C C Harris
Journal:  Cell Death Differ       Date:  2016-04-22       Impact factor: 15.828

Review 3.  Cerebellum Development and Tumorigenesis: A p53-Centric Perspective.

Authors:  Nicolas J Barthelery; James J Manfredi
Journal:  Trends Mol Med       Date:  2016-04-13       Impact factor: 11.951

Review 4.  Therapeutic targeting of the p53 pathway in cancer stem cells.

Authors:  Varun V Prabhu; Joshua E Allen; Bo Hong; Shengliang Zhang; Hairong Cheng; Wafik S El-Deiry
Journal:  Expert Opin Ther Targets       Date:  2012-09-24       Impact factor: 6.902

5.  The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf.

Authors:  Wei Su; Stephanie Hopkins; Nicole K Nesser; Bryce Sopher; Aurelio Silvestroni; Simon Ammanuel; Suman Jayadev; Thomas Möller; Jonathan Weinstein; Gwenn A Garden
Journal:  J Immunol       Date:  2013-12-06       Impact factor: 5.422

6.  Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database.

Authors:  Lyubov E Salnikova
Journal:  Neuromolecular Med       Date:  2014-01-31       Impact factor: 3.843

7.  Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.

Authors:  Hao You; Yao Wu; Kai Chang; Xiao Shi; Xin-Da Chen; Wei Yan; Rui Li
Journal:  CNS Neurosci Ther       Date:  2017-09-03       Impact factor: 5.243

8.  The Regulation of Multiple p53 Stress Responses is Mediated through MDM2.

Authors:  Wenwei Hu; Zhaohui Feng; Arnold J Levine
Journal:  Genes Cancer       Date:  2012-03

9.  p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.

Authors:  Mehrnoosh Tashakori; Yun Zhang; Shunbin Xiong; M James You; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2015-11-02       Impact factor: 5.852

10.  Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.

Authors:  Laura C Armstrong; Grant Westlake; John P Snow; Bryan Cawthon; Eric Armour; Aaron B Bowman; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2017-12-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.